about
Review and uses of stereotactic body radiation therapy for oligometastasesStereotactic body radiation therapy for liver metastasesNew Perspectives in the Treatment of Colorectal MetastasesImaging biomarkers in primary brain tumours.Are pitch and roll compensations required in all pathologies? A data analysis of 2945 fractions.Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Feasibility and tolerability in elderly and chemotherapy-ineligible patients.Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach.Overall and disease-free survival greater than 12 years in metastatic non-small cell lung cancer after linear accelerator-based stereotactic radiosurgery for solitary brain metastasis.Temozolomide combined with radiotherapy in the treatment of recurrent cranial meningioma previously treated with multiple surgical resections and two sessions of radiosurgery: a case report and literature review.Radiation therapy of anal canal cancer: from conformal therapy to volumetric modulated arc therapyIncreased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease.Feasibility and early clinical assessment of flattening filter free (FFF) based stereotactic body radiotherapy (SBRT) treatments.Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma.Performance of a Knowledge-Based Model for Optimization of Volumetric Modulated Arc Therapy Plans for Single and Bilateral Breast Irradiation.Assessment of prognostic factors in patients with metastatic epidural spinal cord compression (MESCC) from solid tumor after surgery plus radiotherapy: a single institution experience.Can advanced new radiation therapy technologies improve outcome of high grade glioma (HGG) patients? analysis of 3D-conformal radiotherapy (3DCRT) versus volumetric-modulated arc therapy (VMAT) in patients treated with surgery, concomitant and adjuvOutcome Evaluation of Oligometastatic Patients Treated with Surgical Resection Followed by Hypofractionated Stereotactic Radiosurgery (HSRS) on the Tumor Bed, for Single, Large Brain Metastases.Toxicity profile and early clinical outcome for advanced head and neck cancer patients treated with simultaneous integrated boost and volumetric modulated arc therapy.Stereotactic Body Radiation Therapy: A useful weapon in anticancer treatment.Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments.Hypofractionated Stereotactic Radiation Therapy in Recurrent High-Grade Glioma: A New Challenge.Volumetric-modulated arc stereotactic body radiotherapy for prostate cancer: dosimetric impact of an increased near-maximum target dose and of a rectal spacer.The role of stereotactic body radiation therapy (SBRT) in the treatment of oligometastatic disease in the elderlyVolumetric modulated arc therapy with flattening filter free beams for isolated abdominal/pelvic lymph nodes: report of dosimetric and early clinical results in oligometastatic patients.[Advantages of a system of positioning and localization made of thermo-conformable materials for irradiation of cervicofacial and encephalic lesions treated with stereotactic fractionated radiation]Intramedullary astrocytoma with granular cell differentiation.Hypo-fractionated stereotactic radiotherapy alone using volumetric modulated arc therapy for patients with single, large brain metastases unsuitable for surgical resectionSBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience.Dosimetric impact of inter-observer variability for 3D conformal radiotherapy and volumetric modulated arc therapy: the rectal tumor target definition case.Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical resultsInitial experience of hypofractionated radiation retreatment with true beam and flattening filter free beam in selected case reports of recurrent nasopharyngeal carcinoma.Feasibility of stereotactic body radiation therapy with volumetric modulated arc therapy and high intensity photon beams for hepatocellular carcinoma patients.Volumetric modulated arc therapy for thoracic node metastases: a safe and effective treatment for a neglected disease.Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments.Postoperative radiotherapy in prostate cancer: acquired certainties and still open issues. A review of recent literature.Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review.Salvage therapy of intraprostatic failure after radical external-beam radiotherapy for prostate cancer: a review.Salvage therapy of small volume prostate cancer nodal failures: a review of the literature.Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography.Outcome Evaluation of Patients with Limited Brain Metastasis From Malignant Melanoma, Treated with Surgery, Radiation Therapy, and Targeted Therapy.
P50
Q26864247-A0C5C36F-786D-430B-A46E-1A6C7378C8FAQ27008308-4D62FD77-54AF-4F88-A3BB-303FD15F2C7DQ28073788-99A3071F-D6B1-4723-987B-33C43224653AQ30880129-FF7D6879-B704-492F-A202-33EB42CD1797Q30995530-5062DA36-9049-43EA-996F-4F6F5FC1A794Q33398899-A6939587-5C16-489D-8E4B-6586878227F0Q34196471-1E99562C-CDCF-46CE-888C-D54392CB31A0Q34296681-BE4BFF26-1CAB-47F6-82F1-652E8DD2B598Q34349003-B611BBF1-7B74-4CF8-BF83-CD0776981330Q34584811-83A372C2-197F-4AF3-B895-3B289D355F7CQ35149263-005E7849-6C02-4E88-B0BE-BEA28EDDF019Q35232033-DB620EF2-550C-4286-B106-FC748DF89303Q35676452-5D3EDE66-1D18-4EB9-A0AF-519B49D4AAA9Q35874856-513A320E-A062-4AF4-9514-3822F2D27AB2Q35886218-D35EB663-AC6A-42DF-86CD-251DDB028776Q36048800-4CA67E44-191E-4613-B5D9-F7146A1FF6B3Q36062550-495A6645-AED4-4E84-8719-0C56BB055828Q36259231-7B8A1E1C-8B11-4BF4-B4EE-CF73DCAFB88BQ36323329-781A4E82-CEAF-40E6-82C8-40C0B90C5D00Q36368120-FF0BBFCB-E7E5-4AF2-B4AF-913C92E3CE5DQ36482578-E72B7434-61FD-415A-90E1-5C795C24FFE6Q36535570-FF692F1E-CCB1-441A-89A4-B999CA56FD66Q36550917-ACA28F6F-1428-4601-8B72-7240289BD11BQ36552596-C78127E1-F88D-4D7C-AC5A-E1428CA74E74Q36703896-FC765C6F-63F7-4FAE-9608-3431BB993A60Q36812907-D9D7DB10-FC0B-43F8-AF6B-AA18CBC750A8Q36960065-2A639F52-4494-421B-A1D7-45038F373665Q37000899-AC28AA0C-4522-400F-BFF1-86A67CC9C271Q37038061-83AA3601-20C7-433D-B5E4-8922284C93B4Q37263260-191A40D8-F3F2-458E-89C1-DD0E0C931EF7Q37453956-6719984D-8F5E-4DE1-86FB-6E293AF91254Q37613015-BBB0EFA9-D29F-4FA6-9EF4-5A09FB73E910Q37619747-E5207C38-6F7C-4FDA-84D0-0E4D0B019894Q37723610-CE3A9DC1-15C7-4C15-8D64-A774C36A3BA0Q37870119-39CA6268-307C-451D-9721-142D61289328Q37976903-3EF8E556-BC3B-457D-AD30-E0CC77FA441CQ38129578-498BBBFF-36C9-48E4-B4D4-D1FC5A0B4553Q38169396-FF52F8A6-7F89-41E3-9FE1-A7540E36D31DQ38373761-AAD434AF-A74A-421E-B296-51CFE8266E56Q38376086-FC333A32-14D8-40AA-89E1-1C4F049A3495
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marta Scorsetti
@ast
Marta Scorsetti
@en
Marta Scorsetti
@es
Marta Scorsetti
@sl
type
label
Marta Scorsetti
@ast
Marta Scorsetti
@en
Marta Scorsetti
@es
Marta Scorsetti
@sl
prefLabel
Marta Scorsetti
@ast
Marta Scorsetti
@en
Marta Scorsetti
@es
Marta Scorsetti
@sl
P108
P106
P21
P31
P496
0000-0003-0320-559X